(Q35925538)

11 August 2017

1 reference

title

Review of the use of topotecan in ovarian carcinoma (English)

1 reference

11 August 2017

Tanya Ahmad

1

1 reference

11 August 2017

Martin Gore

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

2333-2340

1 reference

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Synergistic interaction between topotecan and microtubule-interfering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

The use of oral cytotoxic and cytostatic drugs in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2333

10.1517/14656566.5.11.2333

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference